Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis:A remarkable option

Journal of Investigational Allergology and Clinical Immunology

Volumn 21, Issue 4, 2011, Pages 319-321

  Abadoglu, O ^a   Epozturk, K ^a   Atayik, E ^a   Kaptanoglu, E ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Desensitization; Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; AMLODIPINE; ETANERCEPT; MEPREDNISONE; MONOCLONAL ANTIBODY; PHENIRAMINE; RITUXIMAB;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; DESENSITIZATION; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE ERYTHEMA; INTRACUTANEOUS TEST; LABIAL ANGIOEDEMA; ORAL BLEEDING; PAPULAR URTICARIA; PRICK TEST; RHEUMATOID ARTHRITIS; SKIN TINGLING; SYNCOPE; TACHYCARDIA; TONGUE SWELLING;

ADULT; AMLODIPINE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; PHENIRAMINE; PREMEDICATION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959463486     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Martínez-Gamboa L, Brezinschek HP, Burmester GR, Dorner T. Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev. 2006;5:437-42.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Effi cacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-81.
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Effi cacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-81.
4. Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK. Overview of the clinical development of rituximab: fi rst monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999 Oct;26(5 Suppl 14):66-73.
5. Brennan PJ, Rodríguez Bouza T, Hsu FI, Sloane DE, Castells MC Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259-66.
6. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574-80.
7. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259-66.
8. Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg. 2009;6:13-9.
9. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13:725-32.